NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PYPD

Polypid Ltd

Jun 30 • 04:00PM ET

3.53

Dollar change -0.04
Percentage change -1.12	%

Healthcare • Biotechnology • Israel • NASD

Peers: XTLB MRNS ANIP ATHE EPIX AVDL BCTX AUTL IMUX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.31	Insider Own	34.66%	Shs Outstand	10.19M	Perf Week	-4.08%
Market Cap	35.97M	Forward P/E	-	EPS next Y	-0.90	Insider Trans	0.00%	Shs Float	6.66M	Perf Month	26.52%
Enterprise Value	36.60M	PEG	-	EPS next Q	-0.55	Inst Own	29.64%	Short Float	4.63%	Perf Quarter	28.83%
Income	-30.84M	P/S	-	EPS this Y	64.66%	Inst Trans	36.28%	Short Ratio	0.67	Perf Half Y	18.86%
Sales	0.00M	P/B	418.25	EPS next Y	47.98%	ROA	-146.02%	Short Interest	0.31M	Perf YTD	16.12%
Book/sh	0.01	P/C	4.39	EPS next 5Y	52.99%	ROE	-853.05%	52W High	4.49 -21.38%	Perf Year	-14.11%
Cash/sh	0.80	P/FCF	-	EPS past 3/5Y	-29.21% -37.40%	ROIC	-2041.16%	52W Low	2.30 53.48%	Perf 3Y	-97.65%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.35% 8.33%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	50.76%	Oper. Margin	-	ATR (14)	0.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.71	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.24	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.71	EPS Q/Q	48.81%	SMA20	3.62%	Beta	1.32	Target Price	12.75
Payout	-	Debt/Eq	98.11	Sales Q/Q	-	SMA50	17.22%	Rel Volume	0.19	Prev Close	3.57
Employees	61	LT Debt/Eq	15.89	Earnings	May 14 BMO	SMA200	13.88%	Avg Volume	463.62K	Price	3.53
IPO	Jun 26, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	14.63% -	Trades		Volume	88,892	Change	-1.12%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-25	Initiated	Roth Capital	Buy	$9
Jun-02-25	Resumed	H.C. Wainwright	Buy	$11
Jan-28-25	Initiated	Rodman & Renshaw	Buy	$13
Sep-14-21	Initiated	JMP Securities	Mkt Outperform	$14
Jul-30-21	Initiated	Cantor Fitzgerald	Overweight	$24
Nov-24-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-10-20	Initiated	Alliance Global Partners	Buy	$27
Jul-21-20	Initiated	Raymond James	Outperform	$23
Jul-21-20	Initiated	BMO Capital Markets	Outperform	$30
Jul-21-20	Initiated	Barclays	Overweight	$22

Jun-22-25 06:15AM	Analysts Predict Up to ~590% Spike for These 2 Strong Buy Penny Stocks (TipRanks)
Jun-16-25 07:20PM	PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results (GlobeNewswire) +7.62%
Jun-09-25 12:53PM	Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial (Benzinga)
07:30AM	PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX100 Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints (GlobeNewswire)
Jun-06-25 04:05PM	PolyPid to Host Conference Call and Webcast to Discuss D-PLEX100 SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 (GlobeNewswire)
09:40AM	Loading…
09:40AM	Salesforce initiated, Dollar Tree upgraded: Wall Streets top analyst calls (TipRanks)
May-20-25 07:00AM	PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 (GlobeNewswire)
May-15-25 03:10AM	PolyPid Ltd (PYPD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
May-14-25 07:00AM	PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) +7.01%
Apr-29-25 07:00AM	PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 (GlobeNewswire)
Apr-22-25 07:00AM	PolyPid to Participate in The Citizens Life Sciences Conference (GlobeNewswire)
Mar-18-25 03:30PM	Q1 Virtual Investor Summit: On-Demand Presentations Now Live (ACCESS Newswire)
Mar-11-25 07:00AM	PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections (GlobeNewswire)
Mar-03-25 07:00AM	PolyPid to Participate in the 37th Annual ROTH Conference (GlobeNewswire) -8.29%
Feb-13-25 02:09AM	PolyPid Ltd (PYPD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D Costs (GuruFocus.com)
07:00AM	Loading…
Feb-12-25 07:00AM	PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Jan-30-25 07:00AM	PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-29-25 07:00AM	PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025 (GlobeNewswire)
Dec-23-24 07:22PM	PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX to 800 Patients with a Concurrent Private Placement of up to $41 Million (GlobeNewswire) +14.29% -19.29%
Dec-12-24 07:16AM	PolyPid announces research, development collaboration with ImmunoGenesis (TipRanks) -7.53%
Dec-11-24 07:00AM	PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy (GlobeNewswire)
Nov-29-24 01:05PM	PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance (GlobeNewswire)
Nov-14-24 02:08AM	PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Nov-13-24 07:00AM	PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-07-24 07:00AM	PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference (GlobeNewswire)
Oct-30-24 08:00AM	PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024 (GlobeNewswire)
Oct-23-24 07:01PM	Rosalind Advisors, Inc. Reduces Stake in PolyPid Ltd (GuruFocus.com) +5.59%
Oct-21-24 07:00AM	PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery (GlobeNewswire) -8.08%
Oct-01-24 07:00AM	PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections (GlobeNewswire)
Sep-03-24 07:00AM	PolyPid to Participate in Three Upcoming Fall Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Aug-14-24 07:00AM	PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 08:31PM	PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds (GlobeNewswire)
Jul-31-24 07:00AM	PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024 (GlobeNewswire)
Jun-18-24 07:00AM	PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial (GlobeNewswire)
Jun-10-24 07:00AM	PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX100 Phase 3 Trial (GlobeNewswire)
May-10-24 05:25PM	PolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.39% -8.22%
May-08-24 11:56AM	PYPD Stock Earnings: PolyPid Beats EPS for Q1 2024 (InvestorPlace) -11.32%
07:00AM	PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-01-24 07:00AM	PolyPid to Participate in Citizens JMP Life Sciences Conference (GlobeNewswire)
Apr-30-24 07:00AM	PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections (GlobeNewswire)
Apr-24-24 07:00AM	PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024 (GlobeNewswire)
Feb-28-24 07:00AM	PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference (GlobeNewswire) +8.68%
Feb-19-24 12:00PM	PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Feb-15-24 09:41AM	PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-14-24 07:00AM	PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) -8.21%
Feb-12-24 07:00AM	PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial (GlobeNewswire)
Jan-31-24 07:00AM	PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024 (GlobeNewswire)
Jan-04-24 04:32PM	PolyPid Announces Private Placement for $16 Million in Gross Proceeds (GlobeNewswire) -5.67% +16.36%
Nov-12-23 10:40AM	PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:00AM	PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-07-23 07:00AM	PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors (GlobeNewswire) +7.88%
Nov-01-23 07:00AM	PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023 (GlobeNewswire)
Oct-11-23 07:00AM	PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule (GlobeNewswire)
Oct-09-23 07:00AM	PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023 (GlobeNewswire)
Oct-04-23 07:00AM	PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX and PLEX Technology Platform (GlobeNewswire)
Sep-22-23 07:00AM	PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) -9.24%
Sep-21-23 07:34AM	PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health (GlobeNewswire) -11.74%
Sep-20-23 09:15AM	PolyPid Announces Reverse Share Split (GlobeNewswire) +22.06%
Sep-19-23 07:00AM	PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX (GlobeNewswire) -10.00%
Aug-09-23 07:00AM	PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire) -11.73%
Jul-26-23 07:00AM	PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023 (GlobeNewswire)
Jun-29-23 08:00AM	PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections (GlobeNewswire)
Jun-22-23 07:00AM	PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX for Prevention of Abdominal Colorectal Surgical Site Infections (GlobeNewswire)
Jun-05-23 04:02PM	PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market (GlobeNewswire)
May-22-23 09:00AM	PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX for Prevention of Abdominal Colorectal Surgical Site Infections (GlobeNewswire) -6.26%
May-13-23 12:30PM	PolyPid Ltd. (NASDAQ:PYPD) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-10-23 07:00AM	PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
Apr-26-23 07:00AM	PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023 (GlobeNewswire)
Apr-24-23 07:00AM	PolyPid to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-14-23 04:01PM	PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders Equity Non-Compliance (GlobeNewswire) +5.01%
Mar-31-23 12:00PM	PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds (GlobeNewswire) +6.26%
Mar-29-23 07:59AM	PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants (GlobeNewswire) -16.86%
Mar-28-23 04:05PM	PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares (GlobeNewswire)
Mar-07-23 08:00AM	PolyPid to Present at the Barclays Global Healthcare Conference (GlobeNewswire) +5.34%
Feb-09-23 03:22PM	PolyPid Ltd. (NASDAQ:PYPD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-08-23 07:00AM	PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -12.81%
Jan-31-23 07:00AM	PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023 (GlobeNewswire)
Jan-24-23 07:00AM	PolyPid Provides Positive Regulatory Update for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery (GlobeNewswire) +10.20%
Jan-03-23 07:00AM	PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX in the Prevention of Surgical Site Infections in Abdominal Surgery (GlobeNewswire) +6.95%
Dec-12-22 07:00AM	PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery (GlobeNewswire)
Dec-09-22 04:01PM	PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire) -6.16%
Nov-29-22 07:00AM	PolyPid Announces Presentation of Phase 2 D-PLEX Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association (GlobeNewswire)
Nov-09-22 07:00AM	PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire) -9.59%
Oct-26-22 07:00AM	PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022 (GlobeNewswire)
Oct-20-22 07:09AM	PolyPid Announces Cost Reduction Plan (GlobeNewswire)
Sep-28-22 08:57AM	PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery (GlobeNewswire)
Sep-19-22 07:00AM	PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX in the Prevention of Surgical Site Infections in Abdominal Surgery (GlobeNewswire)
Sep-12-22 07:00AM	PolyPid Announces Presentation of Phase 2 D-PLEX Clinical Data at the European Society for Coloproctology Scientific Conference (GlobeNewswire) +58.33%
Sep-06-22 03:25PM	This Analyst Sees Recovery For PolyPid Despite Failed Phase 3 Readout (Benzinga) -19.58%
Sep-02-22 10:04AM	PolyPid's Lead Program Flunks Abdominal Surgery Study, Shares Tank (Benzinga) -73.47%
08:37AM	PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery (GlobeNewswire)
Aug-31-22 09:55AM	Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 206%: Read This Before Placing a Bet (Zacks) -5.64%
09:40AM	Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-30-22 07:00AM	PolyPid Announces Presentation at the 2022 Military Health System Research Symposium (GlobeNewswire)
Aug-15-22 12:00PM	All You Need to Know About PolyPid Ltd. (PYPD) Rating Upgrade to Buy (Zacks) +5.13%
09:55AM	Wall Street Analysts Believe PolyPid Ltd. (PYPD) Could Rally 223%: Here's is How to Trade (Zacks)
Aug-10-22 07:00AM	PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-03-22 07:00AM	PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX in Europe (GlobeNewswire) +7.83%
Jul-27-22 07:00AM	PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022 (GlobeNewswire) +5.97%

PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PYPD

Polypid Ltd

Upgrade your FINVIZ experience